Guillain-Barre syndrome (GBS) is an immune-mediated, often post-infectious illness manifesting as an acute, characteristically monophasic, polyradiculoneuropathy. We present a case of GBS with autonomic involvement following an mRNA-based vaccine against SARS-COV2 (Pfizer/BioNTech mRNA-BNT162b2). A 58-year-old woman presented with fatigue, distal extremity paresthesias, and severe back pain within 3 days after receiving her first vaccine dose. She developed worsening back pain and paresthesias in distal extremities which prompted her initial presentation to the hospital. By the third week post-vaccine, she developed increasing gait unsteadiness, progression of paresthesias, and new autonomic symptoms including presyncopal episodes and constipation. Neurological exam showed bilateral distal predominant lower extremity weakness, decreased sensation in a length-dependent pattern, and areflexia. EMG/NCS showed a diffuse sensorimotor polyneuropathy with mixed demyelinating and axonal features consistent with GBS. She was treated with 2 g/kg of IVIG over 3 days and also received prednisone 60 mg daily for 3 days for severe back pain, with improvement of symptoms. This possible association with mRNA-based vaccination expands the potential triggers for an autoimmune-based attack on the peripheral nervous system.

1. Brito Ferreira, ML, Militão de Albuquerque, Md. FP, de Brito, CAA, et al. Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: A prospective observational study. Lancet Neurol. 2020;19(10):826-839.
Google Scholar | Crossref | Medline2. Perez-Vilar, S, Hu, M, Weintraub, E, et al. Guillain-Barré syndrome after high-dose influenza vaccine administration in the United States, 2018-2019 season. J Infect Dis. 2021;223(3):416-425.
Google Scholar | Crossref | Medline3. Polack, FP, Thomas, SJ, Kitchin, N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;385(19):1761-1773.
Google Scholar4. Ogbebor, O, Seth, H, Min, Z, Bhanot, N. Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association. IDCases. 2021;24:e01143.
Google Scholar | Crossref | Medline5. Waheed, S, Bayas, A, Hindi, F, Rizvi, Z, Espinosa, PS. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13(2):e13426.
Google Scholar | Medline6. Allen, CM, Ramsamy, S, Tarr, AW, et al. Guillain-Barré syndrome variant occurring after SARS‐CoV‐2 vaccination. Ann Neurol. 2021;90:315-318.
Google Scholar | Crossref | Medline7. Neuromuscular Disease Center at Washington University School of Medicine, Department of Neurology . Neuromuscular Clinical Laboratory Antibody Tests. Requisitions. Published June 29, 2021. https://neuromuscular.wustl.edu/lab/reqs.htm. Accessed November 1, 2021.
Google Scholar8. Kabore, R, Magy, L, Boukhris, S, Mabrouk, T, Lacoste, M, Vallat, JM. Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome. Rev Neurol. 2004;160(8-9):821-823.
Google Scholar | Crossref | Medline9. Querol, L, Nogales-Gadea, G, Rojas-Garcia, R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82(10):879-886.
Google Scholar | Crossref | Medline10. Patone, M, Handunnetthi, L, Saatci, D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. London: Nature Medicine; 2021.
Google Scholar